Foetal liver infusion in a chronic myeloid leukemia patient with busulphan toxicity.
A 36-year-old man suffering from chronic myeloid leukemia (in chronic phase) was initially treated with busulphan. At the end of 6 months of follow-up he developed bone marrow aplasia. He was given single foetal liver infusion therapy. The patient recovered fully from aplasia. He continued in chronic phase for more than 7 years with intermittent busulphan therapy.
Sharma
S
S
Department of Laboratory Medicine (Haematology), Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi.
Kochupillai
V
V
Pati
H P
HP
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D002066:Busulfan / Q000009:adverse effects*; D005333:Fetus; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008099:Liver; D008297:Male
D018906:Antineoplastic Agents, Alkylating; D002066:Busulfan